Medpace

{{Infobox company

| name = Medpace Holdings, Inc.

| logo = Medpace logo.svg

| former_name = Medical Research Services (1992-bef.2014)

| type = Public

| traded_as = {{ubl|{{NASDAQ|MEDP}}|S&P 400 component}}

| area_served = {{increase}} Over 40 countries (2023)

| key_people = August J. Troendle (CEO & chairman of the board of directors)

| industry = Contract Research Organization

| products = Support services for pharmaceutical, biotech, and medical device companies

| revenue = {{US$|1.46 billion|link=yes}} (2022)

| num_employees = {{increase}} 5,400 (2023)

| founded = {{Start date and age|1992}}

| hq_location = Cincinnati, Ohio, U.S.

| website = {{URL|medpace.com}}

| footnotes =

}}

Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio,{{cite news|url=http://medcitynews.com/2011/06/mid-sized-cros-perform-as-good-or-better-than-larger-ones-survey-says/|title=Mid-sized CROs perform as good or better than larger ones, survey says|last=Vinluan|first=Frank|date=14 June 2011|newspaper=MedCity News|access-date=31 Aug 2019|publisher=Breaking Media|location=New York, New York|quote=The strong performance of mid-sized CROs was evident in the category for speed of site and investigator recruitment. Cincinnati, Ohio-based MedPace was the highest scoring CRO in survey responses for that category while large CROs such as Covance, Parexel, PPD, PRA International and Quintiles all received negative marks.}}{{cite web |url=http://seekingalpha.com/news/3190516-medpace-holdings-files-raise-150m-ipo |access-date=2016-06-26 |date=24 June 2016 |title=Medpace Holdings files to raise up to $150M in IPO |last=Aycock |first=Jason |website=Seeking Alpha }}{{cite web |url=https://www.sec.gov/Archives/edgar/data/1668397/000119312516631490/d125783ds1.htm |access-date=2016-06-26 |date=24 June 2016 |title=S-1 |website=EDGAR }} employing approximately 5,400 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.

The company started trading stock as a public firm in 2016.

History

August Troendle founded Medpace in Cincinnati, Ohio, in 1992 as Medical Research Services.{{Cite news|url=https://www.bizjournals.com/cincinnati/news/2016/08/22/cincinnati-ceo-buys-20m-worth-of-stock-in-ipo.html|title=Cincinnati CEO buys $20M worth of stock in IPO|last=Brunsman|first=Barrett J.|date=22 August 2016|work=Cincinnati Business Courier|access-date=31 Aug 2019|publisher=American City Business Journals|quote=After the Aug. 16 transaction, Troendle directly owned more than 1.2 million shares of Medpace.}} Troendle first became interested in the CRO sector after working in both the regulatory and pharmaceutical area. He began his career as a reviewer with the FDA, specializing in the development of lipid lowering therapies to treat high cholesterol.

With a team of industry physicians, Jonathan Issacsohn and Evan Stein completed many early studies while at Medpace and Medpace Reference Laboratories on the use of statin therapies for the treatment of hypercholesterolemia.{{cite journal|author=Jonathan Isaacsohn M.D., William Insull JR., M.D., Evan Stein M.D.Ph.D., Peter Kwiterovich M.D., Ma Patrick M.D., Ronald Brazg M.D., Carlos A. Dujovne M.D., Michael Shan PH.D., Elizabeth Shugrue-Crowley B.S., Steven Ripa M.D., Robert Tota M.D.|title=Long-Term Efficacy and Safety of Cerivastatin 0.8 mg in Patients with Primary Hypercholesterolemia|journal=Clinical Cardiology|date=September 2001|volume=24|issue=Supplement S4|pages=IV1-9|doi=10.1002/clc.4960240902|pmid=11594407|pmc=6655191}} Another Medpace physician, David Orloff was regarded as an industry opinion leader in the study of metabolic diseases – most specifically diabetes and obesity.{{cite web|last=Orloff|first=David|title=Interview with Dr. David Orloff|url=http://www.organizedwisdom.com/interview-with-dr-david-orloff-pharmaceutical-business-review/5563235/nxi/med|work=August 23, 2011|publisher=Pharmaceutical Business Review|access-date=10 April 2013}} Troendle was honored for his work as a Medpace founder in 2012 by the Cincinnati Chamber of Commerce.{{cite web|last=Hirt|first=Amy|title=Courier Contributor|url=http://www.bizjournals.com|work=Cincinnati Business Courier|publisher=The Business Journals Digital Network|access-date=9 April 2013}}

Medpace completed construction on a new campus in 2012 in Madisonville, a neighborhood on the eastern side of Cincinnati.{{cite web|title=Medpace Construction Ranks 3rd behind downtown mega projects|url=http://www.historicmadisonville.com/home/business-economic-development|work=April 2010|access-date=10 April 2013}} The project encompassed revitalizing an urban brownfield site formerly occupied by NuTone, and creating a state of the art LEED (Leadership in Energy and Environmental Design) certified campus.{{cite web|title=Brownfield Redevelopment|url=http://www.cincinnati-oh.gov/oeq/citywide-efforts/brownfield-redevelopment/|work=cincinnati-oh.gov|access-date=9 April 2013|url-status=dead|archive-url=https://web.archive.org/web/20130828102648/http://www.cincinnati-oh.gov/oeq/citywide-efforts/brownfield-redevelopment/|archive-date=28 August 2013}}

In 2022, Medpace announced a $150 million capital investment to expand its headquarters in Cincinnati, Ohio, adding an estimated expansion of 1,500 new jobs.

= Acquisitions =

2007 – Medpace acquires Monax in the Czech Republic{{cite news|title=Medpace acquires Czech CRO|url=http://www.pharmatimes.com/news/medpace_acquires_czech_cro_monax_990691|access-date=10 April 2013|date=22 August 2007|publisher=Pharma Times}}
2009 – Medpace acquires PharmaBrains AG in Switzerland
2010 – Medpace acquires Symbios, a medical device consultancy in Minneapolis, Minnesota{{cite web|title=Medpace acquires Symbios Clinical|url=http://www.pharmacynews.eu/tag/medpace|work=April 8, 2010|publisher=Pharmacy News EU|access-date=11 April 2013}}
2010 – Medpace acquires Medical Consulting Dr. Schlichtiger, GmbH, in Germany{{cite news|title=Medpace acquires European CRO|url=http://www.contractpharma.com/contents/view_breaking-news/2010-01-18/medpace-acquires-european-cro-/|access-date=10 April 2013|date=January 2010}}
2012 – Medpace acquires MediTech BV, a medical device consultancy in the Netherlands.{{cite news|last=Morrison|first=Natalie|title=Medpace boost EU device offering through Meditech takeover|url=http://www.outsourcing-pharma.com/Commercial-Services/Medpace-boost-EU-device-offering-through-Meditech-takeover|access-date=11 April 2013|newspaper=Outsourcing Pharma|date=20 November 2012}}

Ownership

In 2011, CCMP Capital acquired 80% of the firm for {{US$|285 million}}. Three years later, in February 2014, CCMP auctioned their 80% stake; the winner was won by Cinven, who paid {{US$|900 million}}.{{cite news|url=https://www.reuters.com/article/us-medpace-cinven-idUSBREA1M14020140223|title=Cinven to acquire Medpace in $900 million deal: sources|last=Roumeliotis|first=Greg|date=23 February 2014|access-date=31 Aug 2019|work=Reuters}} In August 2017, Medpace went became a publicly-traded company with its initial public offering, selling 8,050,000 shares of common stock.